Evidence map›Paper›PMID 36522523›Full record

ArticleHuman cell2023

Induction of premature senescence and a less-fibrogenic phenotype by programmed cell death 4 knockdown in the human hepatic stellate cell line Lieming Xu-2.

Rasheda Perveen, Iwata Ozaki, M Manirujjaman, Keiichiro Mine, Yuzo Murata, Kenichi Tanaka, Jinghe Xia, Hirokazu Takahashi, Keizo Anzai, Sachiko Matsuhashi

Open access · hybridAbstract read
In one paragraph

Article in Human cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Rasheda PerveenDivision of Hepatology, Diabetology and Endocrinology, Department of Internal Medicine, Saga Medical School, Saga University, 5-1-1 Nabeshima, Saga, Saga, 849-8501, Japan.
Iwata OzakiDivision of Hepatology, Diabetology and Endocrinology, Department of Internal Medicine, Saga Medical School, Saga University, 5-1-1 Nabeshima, Saga, Saga, 849-8501, Japan. ozaki@cc.saga-u.ac.jp.ORCID http://orcid.org/0000-0001-8542-1434
M ManirujjamanDivision of Hepatology, Diabetology and Endocrinology, Department of Internal Medicine, Saga Medical School, Saga University, 5-1-1 Nabeshima, Saga, Saga, 849-8501, Japan.
Keiichiro MineDivision of Hepatology, Diabetology and Endocrinology, Department of Internal Medicine, Saga Medical School, Saga University, 5-1-1 Nabeshima, Saga, Saga, 849-8501, Japan.
Yuzo MurataDepartment of Pharmaceutical Sciences, School of Pharmacy at Fukuoka, International University of Health and Welfare, 137-1 Enokizu, Ohkawa, Fukuoka, 831-8501, Japan.
Kenichi TanakaDivision of Hepatology, Diabetology and Endocrinology, Department of Internal Medicine, Saga Medical School, Saga University, 5-1-1 Nabeshima, Saga, Saga, 849-8501, Japan.
Jinghe XiaDivision of Hepatology, Diabetology and Endocrinology, Department of Internal Medicine, Saga Medical School, Saga University, 5-1-1 Nabeshima, Saga, Saga, 849-8501, Japan.
Hirokazu TakahashiDivision of Hepatology, Diabetology and Endocrinology, Department of Internal Medicine, Saga Medical School, Saga University, 5-1-1 Nabeshima, Saga, Saga, 849-8501, Japan.
Keizo AnzaiDivision of Hepatology, Diabetology and Endocrinology, Department of Internal Medicine, Saga Medical School, Saga University, 5-1-1 Nabeshima, Saga, Saga, 849-8501, Japan.
Sachiko MatsuhashiDivision of Hepatology, Diabetology and Endocrinology, Department of Internal Medicine, Saga Medical School, Saga University, 5-1-1 Nabeshima, Saga, Saga, 849-8501, Japan.
Saga University · JPFukuoka International University · JP

Funding

Japan Society for the Promotion of Science 16590606
6 · The paper itself

Abstract

Although programmed cell death 4 (PDCD4) was initially reported as a tumor suppressor and has been shown to inhibit cancer cell growth and metastasis, recent studies have demonstrated that loss of PDCD4 expression also induces growth inhibition by inducing apoptosis and/or cellular senescence. At present, the roles of PDCD4 in the activation and profibrogenic properties of myofibroblasts, which are critically involved in organ fibrosis, such as that in the liver, are unclear. We, therefore, investigated the roles of PDCD4 in myofibroblasts using human hepatic stellate cell line Lieming Xu-2 (LX-2). PDCD4 knockdown inhibited LX-2 proliferation and induced a senescent phenotype with increased β-galactosidase staining and p21 expression in a p53-independent manner together with downregulation of the notch signaling mediator RBJ-κ/CSL. During PDCD4 knockdown, alpha smooth muscle actin (α-SMA; an activation marker of myofibroblasts), matrix metalloproteinases MMP-1 and MMP-9, and collagen IV were upregulated, but the expression of collagen1α1 and collagen III was markedly downregulated without any marked change in the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1). These results demonstrated that knockdown of PDCD4 induced the cellular senescence phenotype and activated myofibroblasts while suppressing the profibrogenic phenotype, suggesting roles of PDCD4 in cellular senescence and fibrogenesis in the liver.

Indexed as

Apoptosis Regulatory ProteinsHepatic Stellate CellsRNA-Binding ProteinsApoptosisCollagenHumansPhenotypeTissue Inhibitor of Metalloproteinase-1Apoptosis Regulatory ProteinsCollagenPDCD4 protein, humanRNA-Binding ProteinsTissue Inhibitor of Metalloproteinase-1FibrosisHepatic stellate cellp21PDCD4Senescenceα-SMA

Identifiers

PMID36522523
PMCPMC9947070
OpenAlexW4311599690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.